patritumab deruxtecan is composed of a fully human anti-HER3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide ...
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...
Initial results from dose escalation in the first in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumours known to express Claudin-6 (CLDN6) ...
TOKYO, Japan & BASKING RIDGE, NJ, USA I 15, 2024 I Initial results from dose escalation in the first-in-human phase 1 trial of DS-9606 suggest ...
Is Efficacious in Human Ovarian and Kidney Cancer Models DXd ADC is a novel ADC therapeutic designed with a potent DNA topoisomerase I inhibitor exatecan delivative. Raludotatug deruxtecan (R-DXd) is ...
(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...
The trial compared the ADC patritumab deruxtecan to chemotherapy in people with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC) after the failure of a third ...
CBX-12 is designed to deliver higher concentrations of exatecan, a topoisomerase 1 (TOP1) inhibitor, directly to tumor cells while sparing healthy tissue. Unlike antibody-drug conjugates, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback